These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

525 related articles for article (PubMed ID: 34144047)

  • 21. Efficacy of Vedolizumab Induction and Maintenance Therapy in Patients With Ulcerative Colitis, Regardless of Prior Exposure to Tumor Necrosis Factor Antagonists.
    Feagan BG; Rubin DT; Danese S; Vermeire S; Abhyankar B; Sankoh S; James A; Smyth M
    Clin Gastroenterol Hepatol; 2017 Feb; 15(2):229-239.e5. PubMed ID: 27639327
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Comparative effectiveness of antitumour necrosis factor agents and vedolizumab in ulcerative colitis.
    Davis R; McParland P; Dodd S; Storey D; Probert C; Collins P; Skouras T; Steel A; Derbyshire E; Dibb M; Subramanian S
    Eur J Gastroenterol Hepatol; 2019 Jun; 31(6):661-667. PubMed ID: 30855421
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Etrolizumab for maintenance therapy in patients with moderately to severely active ulcerative colitis (LAUREL): a randomised, placebo-controlled, double-blind, phase 3 study.
    Vermeire S; Lakatos PL; Ritter T; Hanauer S; Bressler B; Khanna R; Isaacs K; Shah S; Kadva A; Tyrrell H; Oh YS; Tole S; Chai A; Pulley J; Eden C; Zhang W; Feagan BG;
    Lancet Gastroenterol Hepatol; 2022 Jan; 7(1):28-37. PubMed ID: 34798037
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Comparative Safety and Effectiveness of Vedolizumab to Tumor Necrosis Factor Antagonist Therapy for Ulcerative Colitis.
    Lukin D; Faleck D; Xu R; Zhang Y; Weiss A; Aniwan S; Kadire S; Tran G; Rahal M; Winters A; Chablaney S; Koliani-Pace JL; Meserve J; Campbell JP; Kochhar G; Bohm M; Varma S; Fischer M; Boland B; Singh S; Hirten R; Ungaro R; Lasch K; Shmidt E; Jairath V; Hudesman D; Chang S; Swaminath A; Shen B; Kane S; Loftus EV; Sands BE; Colombel JF; Siegel CA; Sandborn WJ; Dulai PS
    Clin Gastroenterol Hepatol; 2022 Jan; 20(1):126-135. PubMed ID: 33039584
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Comparative Efficacy of Subcutaneous and Intravenous Infliximab and Vedolizumab for Maintenance Treatment of TNF-naive Adult Patients with Inflammatory Bowel Disease: A Systematic Literature Review and Network Meta-analysis.
    Peyrin-Biroulet L; Bossuyt P; Bettenworth D; Loftus EV; Anjie SI; D'Haens G; Saruta M; Arkkila P; Park H; Choi D; Kim DH; Reinisch W
    Dig Dis Sci; 2024 May; 69(5):1808-1825. PubMed ID: 38499736
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Comparative efficacy and safety of vedolizumab and infliximab in ulcerative colitis after failure of a first subcutaneous anti-TNF agent: a multicentre cohort study.
    Hupé M; Rivière P; Nancey S; Roblin X; Altwegg R; Filippi J; Fumery M; Bouguen G; Peyrin-Biroulet L; Bourreille A; Caillo L; Simon M; Goutorbe F; Laharie D
    Aliment Pharmacol Ther; 2020 May; 51(9):852-860. PubMed ID: 32201971
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Translating Results from VARSITY to Real World: Adalimumab vs Vedolizumab as First-line Biological in Moderate to Severe IBD.
    Moens A; Verstockt B; Alsoud D; Sabino J; Ferrante M; Vermeire S
    Inflamm Bowel Dis; 2022 Aug; 28(8):1135-1142. PubMed ID: 34751766
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Effect of vedolizumab (anti-α4β7-integrin) therapy on histological healing and mucosal gene expression in patients with UC.
    Arijs I; De Hertogh G; Lemmens B; Van Lommel L; de Bruyn M; Vanhove W; Cleynen I; Machiels K; Ferrante M; Schuit F; Van Assche G; Rutgeerts P; Vermeire S
    Gut; 2018 Jan; 67(1):43-52. PubMed ID: 27802155
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Efficacy and safety of prolonged release budesonide granules in mesalazine-refractory ulcerative colitis: A multi-centre Phase IIa study (TOPICAL-1).
    Fellermann K; Schiefke I; Rácz I; Derova J; Jonaitis L; Wehrum S; Nacak T; Greinwald R
    United European Gastroenterol J; 2020 Dec; 8(10):1186-1195. PubMed ID: 33028169
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Early mucosal healing with infliximab is associated with improved long-term clinical outcomes in ulcerative colitis.
    Colombel JF; Rutgeerts P; Reinisch W; Esser D; Wang Y; Lang Y; Marano CW; Strauss R; Oddens BJ; Feagan BG; Hanauer SB; Lichtenstein GR; Present D; Sands BE; Sandborn WJ
    Gastroenterology; 2011 Oct; 141(4):1194-201. PubMed ID: 21723220
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Early Versus Late Use of Vedolizumab in Ulcerative Colitis: Clinical, Endoscopic, and Histological Outcomes.
    Vermeire S; Hanzel J; Löwenberg M; Ferrante M; Bossuyt P; Hoentjen F; Franchimont D; Palatka K; Peeters H; Mookhoek A; de Hertogh G; Molnár T; van Moerkercke W; Lobatón T; Clasquin E; Hulshoff MS; Baert F; D'Haens G;
    J Crohns Colitis; 2024 Apr; 18(4):540-547. PubMed ID: 37934813
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Subcutaneous golimumab maintains clinical response in patients with moderate-to-severe ulcerative colitis.
    Sandborn WJ; Feagan BG; Marano C; Zhang H; Strauss R; Johanns J; Adedokun OJ; Guzzo C; Colombel JF; Reinisch W; Gibson PR; Collins J; Järnerot G; Rutgeerts P;
    Gastroenterology; 2014 Jan; 146(1):96-109.e1. PubMed ID: 23770005
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Effectiveness of adalimumab for the treatment of ulcerative colitis in clinical practice: comparison between anti-tumour necrosis factor-naïve and non-naïve patients.
    Iborra M; Pérez-Gisbert J; Bosca-Watts MM; López-García A; García-Sánchez V; López-Sanromán A; Hinojosa E; Márquez L; García-López S; Chaparro M; Aceituno M; Calafat M; Guardiola J; Belloc B; Ber Y; Bujanda L; Beltrán B; Rodríguez-Gutiérrez C; Barrio J; Cabriada JL; Rivero M; Camargo R; van Domselaar M; Villoria A; Schuterman HS; Hervás D; Nos P;
    J Gastroenterol; 2017 Jul; 52(7):788-799. PubMed ID: 27722996
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Vedolizumab for the Treatment of Chronic Pouchitis.
    Travis S; Silverberg MS; Danese S; Gionchetti P; Löwenberg M; Jairath V; Feagan BG; Bressler B; Ferrante M; Hart A; Lindner D; Escher A; Jones S; Shen B;
    N Engl J Med; 2023 Mar; 388(13):1191-1200. PubMed ID: 36988594
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Methotrexate Is Not Superior to Placebo for Inducing Steroid-Free Remission, but Induces Steroid-Free Clinical Remission in a Larger Proportion of Patients With Ulcerative Colitis.
    Carbonnel F; Colombel JF; Filippi J; Katsanos KH; Peyrin-Biroulet L; Allez M; Nachury M; Novacek G; Danese S; Abitbol V; Bossa F; Moreau J; Bommelaer G; Bourreille A; Fumery M; Roblin X; Reinisch W; Bouhnik Y; Brixi H; Seksik P; Malamut G; Färkkilä M; Coulibaly B; Dewit O; Louis E; Deplanque D; Michetti P; Sarter H; Laharie D; ;
    Gastroenterology; 2016 Feb; 150(2):380-8.e4. PubMed ID: 26632520
    [TBL] [Abstract][Full Text] [Related]  

  • 36. End of induction patient reported outcomes predict clinical remission and endoscopic improvement with vedolizumab and adalimumab in ulcerative colitis.
    Wong ECL; Hasan B; Dulai PS; Marshall JK; Reinisch W; Narula N
    Scand J Gastroenterol; 2023 Jan; 58(1):7-14. PubMed ID: 35909369
    [TBL] [Abstract][Full Text] [Related]  

  • 37. An International Multicenter Real-Life Prospective Study of Electronic Chromoendoscopy Score PICaSSO in Ulcerative Colitis.
    Iacucci M; Smith SCL; Bazarova A; Shivaji UN; Bhandari P; Cannatelli R; Daperno M; Ferraz J; Goetz M; Gui X; Hayee B; De Hertogh G; Lazarev M; Li J; Nardone OM; Parra-Blanco A; Pastorelli L; Panaccione R; Occhipinti V; Rath T; Tontini GE; Vieth M; Villanacci V; Zardo D; Bisschops R; Kiesslich R; Ghosh S
    Gastroenterology; 2021 Apr; 160(5):1558-1569.e8. PubMed ID: 33347880
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Filgotinib as induction and maintenance therapy for ulcerative colitis (SELECTION): a phase 2b/3 double-blind, randomised, placebo-controlled trial.
    Feagan BG; Danese S; Loftus EV; Vermeire S; Schreiber S; Ritter T; Fogel R; Mehta R; Nijhawan S; Kempiński R; Filip R; Hospodarskyy I; Seidler U; Seibold F; Beales ILP; Kim HJ; McNally J; Yun C; Zhao S; Liu X; Hsueh CH; Tasset C; Besuyen R; Watanabe M; Sandborn WJ; Rogler G; Hibi T; Peyrin-Biroulet L
    Lancet; 2021 Jun; 397(10292):2372-2384. PubMed ID: 34090625
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Decision Support Tool Identifies Ulcerative Colitis Patients Most Likely to Achieve Remission With Vedolizumab vs Adalimumab.
    Dulai PS; Wong ECL; Reinisch W; Colombel JF; Marshall JK; Narula N
    Inflamm Bowel Dis; 2022 Oct; 28(10):1555-1564. PubMed ID: 34967397
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Early Change in Epithelial Neutrophilic Infiltrate Predicts Long-Term Response to Biologics in Ulcerative Colitis.
    Narula N; Wong ECL; Colombel JF; Riddell R; Marshall JK; Reinisch W; Dulai PS
    Clin Gastroenterol Hepatol; 2022 May; 20(5):1095-1104.e9. PubMed ID: 34229037
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 27.